These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12411975)

  • 21. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacological and clinical evidence for the use of low-molecular-weight heparins in acute coronary syndromes.
    Rosito GA; Silva OB; Ribeiro JP
    Arq Bras Cardiol; 2001 Aug; 77(2):184-95. PubMed ID: 11514830
    [No Abstract]   [Full Text] [Related]  

  • 23. New-generation anticoagulants: the low molecular weight heparins.
    Hovanessian HC
    Ann Emerg Med; 1999 Dec; 34(6):768-79. PubMed ID: 10577408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
    Bosanquet N; Jönsson B; Fox KA
    Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The emerging role of low-molecular-weight heparin in cardiovascular medicine.
    Hirsh J; Bates SM
    Prog Cardiovasc Dis; 2000; 42(4):235-46. PubMed ID: 10661777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction.
    Ferrario M; Merlini PA; Lucreziotti S; Poli A; Cantù F; Gobbi G; Bramucci E; Mussini A; Ardissino D
    Int J Cardiol; 1999 Apr; 68 Suppl 1():S63-71. PubMed ID: 10328613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of low-molecular-weight heparins in cardiovascular medicine.
    Hödl R; Klein W
    J Clin Pharm Ther; 2003 Oct; 28(5):371-8. PubMed ID: 14632961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction.
    Weitz JI; Bates SM
    Arch Intern Med; 2000 Mar; 160(6):749-58. PubMed ID: 10737274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory.
    Deutsch E
    Am Heart J; 1999 Dec; 138(6 Pt 2):S577-85. PubMed ID: 10577465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
    Kaul S; Shah PK
    J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-molecular-weight heparins in clinical practice.
    Hunt D
    South Med J; 1998 Jan; 91(1):2-10. PubMed ID: 9438394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight heparins for acute coronary syndrome: tackling the issues head-on.
    Antman EM
    Am Heart J; 2003 Aug; 146(2):191-3. PubMed ID: 12891179
    [No Abstract]   [Full Text] [Related]  

  • 34. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low molecular weight heparins.
    Aguilar OM; Kleiman NS
    Expert Opin Pharmacother; 2000 Sep; 1(6):1091-103. PubMed ID: 11249481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unfractionated heparin in cardiology: redefining the standard of practice.
    Rihn TL; Díez J;
    Pharmacotherapy; 2004 Aug; 24(8 Pt 2):132S-141S. PubMed ID: 15334859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of low-molecular-weight heparin in unstable angina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty].
    Pimentel Filho WA
    Arq Bras Cardiol; 1995 Dec; 65(6):517-8. PubMed ID: 8731307
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New frontiers in the management of unstable coronary artery disease.
    Turpie AG
    Am J Cardiol; 1997 Sep; 80(5A):21E-24E. PubMed ID: 9296465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of low-molecular-weight heparins in the management of unstable angina and non-ST elevation myocardial infarction.
    Alwi I
    Acta Med Indones; 2008 Oct; 40(4):228-32. PubMed ID: 19530369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.